Streptococcus agalactiae isolated in Santa Fe, Argentina: Antibiotic susceptibility and erythromycin-clindamycin resistance mechanisms [2];Streptococcus agalactiae aislados en Santa Fe, Argentina: Estadio de la sensibilidad a antibióticos de uso clínico y mecanismos de resistencia a eritromicina y clindamicina

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 25, Issue 1, 2007, Pages 67-68

  Mollerach, Analía ^a   Méndez, Emilce ^a,b   Massa, Rosana ^c   Di Conza, José ^b  

^a Hospital Jose M Cullen   (Argentina)

^b UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARGENTINA; DRUG MECHANISM; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION;

EID: 33846940032     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13096755     Document Type: Letter

References (12)

1. Schuchat, A. Epidemiology of Group B Streptococcal Disease in the United States: Shifting Paradigms. Clin Microbiol Rev. 1998;11:497-513.
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Eighth Edition (2003). M100 S15. Vol. 25 No 1. Wayne PA. USA.
3. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Sixth Edition (2003). M7 A6. Vol. 23 No 2. Wayne PA. USA.
4. Bozdogan B, Berrezouga L, Kuo MS, Yurek DA, Farley KA, Stockman BJH, et al. A new resistance gene, linB, conferring resistance to lincosamides by nucleotidylation in Enterococcus faecium HM 1025. Antimicrob Agents Chemother. 1999;43:925-9.
5. Sutcliffe J, Thorsten G, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCK. Antimicrob Agents Chemother. 1996;40:2562-6.
6. Truppia L, Mollerach A, Perisutti R, Mendosa A, Méndez E. Susceptibility of 115 strain of Streptococcus agalactiae to different clinical antimicrobial agents. Revista FABICIB. 2001;5:119-23.
7. Betriu C, Culebras E, Gómez M, Rodríguez-Avial I, Sánchez BA, Ágreda MC, et al. Erithromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrob Agents Chemother. 2003;47:1112-4.
8. Lopardo HA, Vidal P, Jeric P, Centron D, Paganini H, Facklam RR, et al. Six-month multicenter study on invasive infections due to group B Streptococci in Argentina. J Clin Microbiol. 2003;4:4688-94.
9. González Pedraza Avilés A, Ortiz Zaragoza MC, Mota Vázquez R. Serotypes and antimicrobial susceptibility of group B Streptococcus isolated from pregnant women in Mexico. Revista Latinoamericana de Microbiología. 2002;44:133-6.
10. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Antimicrob Agents Chemother. 2004;48:323-5.
11. De Azavedo JS, McGavin M, Duncan C, Low DE, McGeer A. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B Streptococcus isolates from Ontario, Canada. Antimicrob Agents Chemother. 2001;45:3504-8.
12. Kowamura Y, Fujiwara H, Mishima N, Tanaka Y, Tanimato A, Ikawa S, et al. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob Agents Chemother. 2003;3605-9.